GSK

News

GSK backs up its Blenrep rehab bid with survival data

GSK has revealed the data it hopes will allow a return to the US market for Blenrep, which was the first BCMA-targeting drug to launch there, but was withdrawn from sale after it fail

News

GSK on top in RSV jab rollout, but is Pfizer closing the gap...

GSK and Pfizer’s full-year financial results show that the former is currently winning the battle for take-up of their rival respiratory syncytial virus (RSV) vaccines, al

News

Novartis calls time on Tim3 drug sabatolimab in MDS

Novartis’ position as the frontrunner in the race to bring a Tim3-targeting drug to market has been lost after it pulled a phase 3 trial of its sabatolimab candidate.

News

GSK’s Omjjara EU-cleared for splenomegaly in myelofibrosis

GSK’s $1.9 billion takeover of Sierra Oncology has delivered the first new product, with the EU approval of Omjjara for the treatment of enlarged spleen (splenomegaly) or

News

Next stage in GSK’s Zantac defense gets underway today

A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients.

News

JPM: GSK announces $1.4bn deal to buy asthma biotech Aiolos

GSK has taken another step towards rebuilding its respiratory pipeline with a $1.4 billion agreement to buy Aiolos Bio and its lead drug AIO-001 for asthma and other indic

GSK backs up its Blenrep rehab bid with survival data

GSK on top in RSV jab rollout, but is Pfizer closing the gap...

Novartis calls time on Tim3 drug sabatolimab in MDS

GSK’s Omjjara EU-cleared for splenomegaly in myelofibrosis

Next stage in GSK’s Zantac defense gets underway today

JPM: GSK announces $1.4bn deal to buy asthma biotech Aiolos

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

GSK

Editor's Picks